The NanoB2A group is a multidisciplinary research team led by Prof. Laura M. Lechuga. We are physicists, engineers, chemists, and biologists working in the broad field of Nanobiotechnology. Our motivation is to develop new and cutting-edge biosensor nanotechnologies using photonics, one of the key technologies of the 21st century, to promote and boost healthcare and well-being for our society.
Our research focuses on the development of photonic point-of-care biosensors and their employment in clinical, biomedical, and environmental areas. We mainly exploit Nanoplasmonics and Silicon Nanophotonics technologies to accomplish integrated biosensing systems for the label-free, real-time, and multiplexed analysis at the point of care. Our activity encompasses the entire process of generating new biosensor devices, including fundamental research and theoretical design, nanofabrication, surface biofunctionalization, lab-on-a-chip integration, and their final validation in real scenarios.
NanoB2A group is established at the Catalan Institute of Nanoscience and Nanotechnology (ICN2), in Barcelona (Spain), belonging to the CERCA network of Catalan Research Institutes and integrated in BIST (Barcelona Institute of Science and Technology). The NanoB2A belongs as well to the Spanish National Research Council (CSIC) and the Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).
At the ICN2, together with Phantoms Foundation, we are organizing the first online conference about COVID19 pandemics. The Biosensors for Pandemics Conference will be streamed worldwide on May 6th, joining top international researchers to discuss how new nanotech diagnostic systems can help in health emergency situations.
Prof. Laura M. Lechuga will give a Keynote presentation about the CoNVat project and how our advanced nanobiosensing platforms are being developed for point-of-care diagnostics and surveillance of coronavirus.
Visit the Conference Website and join us:
The current issue of Optics & Photonics News, the prestigious outreach journal of The Optical Society (OSA), highlights in the cover our recent publication Nanophotonic Biosensors: Driving Personalized Medicine.
In this feature, we provide a clear and understandable overview of the latest advances in optical biosensing platforms and their applications in healthcare. Photonic biosensors are a unique solution to accomplish more informative, timely and precise diagnosis of human diseases, and recently, they are also emerging as alternative tools to help in the development and general widespread of personalized therapies.
Have a look!
SensMOF is the new BIST IGNITE project that will be led by Dr. Leyre Gómez, postdoc in NanoB2A and NanoUP (Prof. Maspoch) groups at ICN2, together with ICREA Professor José Ramón Galán-Mascarós, from ICIQ.
The SensMOF project aims to develop new nanophotonic sensors for quantitative analysis of bioactive enantiomeric molecules, a current and major challenge for the pharmaceutical industry. We will work on a solution based on the so-called homochiral metal-organic frameworks, compounds composed by metal ions and organic ligands able to identify and separate enantiomers. This BIST collaboration will combine the expertise of different teams to create a scalable prototype that addresses the current industrial challenges of scalability and enantiomer separation process cost.